FDA Approves New Oral Solution of Dronabinol, a Key Ingredient in Marinol, for Placement in Schedule II

Summary

The U.S. Food and Drug Administration (FDA) has approved a new oral solution of dronabinol, a key ingredient in Marinol, for placement in Schedule II of the Controlled Substances Act, following a request from the Drug Enforcement Administration (DEA).